White Paper

Strategies for Accelerating the Development of Modified Release Oral Forms

Download now

Blog

Inhalation

Formulation Development Challenges and Pitfalls when Developing Dry Powder Inhalers

5 / 22 posts displayed

Post

How to balance time, costs and development risk when choosing the appropriate dosage form for your first-in-human Phase I trials?
Post

Candidate selection & API characterization: How do we assess the right molecules to take forward into development?
Scientific resources

Quotient's Scientific Achievements in 2019
Site Spotlight

Spotlight on Philadelphia - Q&A with Nutan Gangrade, Managing Director of Quotient Sciences Garnet Valley and Chelsea Parkway
Translational Pharmaceutics

Tuft’s Center for the Study of Drug Development partners with Quotient Sciences for study on Translational Pharmaceutics.

Share Your Development Challenge with our Scientists

Let's Talk

Ask us a question

We use cookies to help us to improve our site and enables us to the best possible service and customer experience. By clicking accept you are agreeing to let us share your data with select third parties for analytics and marketing purposes.

White Paper

Formulation Development Challenges and Pitfalls when Developing Dry Powder Inhalers

How to balance time, costs and development risk when choosing the appropriate dosage form for your first-in-human Phase I trials?

Candidate selection & API characterization: How do we assess the right molecules to take forward into development?

Quotient's Scientific Achievements in 2019

Spotlight on Philadelphia - Q&A with Nutan Gangrade, Managing Director of Quotient Sciences Garnet Valley and Chelsea Parkway

Tuft’s Center for the Study of Drug Development partners with Quotient Sciences for study on Translational Pharmaceutics.

Share Your Development Challenge with our Scientists